Episode
Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2
- Podcast
- HCPLive Podcasts
- Published
- May 28, 2026
- Duration seconds
- 1674
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8909063
Actions
POST https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification. “Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.